Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Cetuximab Stories

2010-11-04 13:12:27

Stereotactic body radiotherapy (SBRT), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, may effectively control and treat head and neck cancers when combined with the chemotherapy Cetuximab, according to researchers from UPCI. The results of the research will be presented today at the American Society for Radiation Oncology (ASTRO) annual meeting in San Diego. The study, led by Dwight...

2010-10-28 22:05:14

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010. Researchers said they don't know why this variant site, a microRNA binding site that should allow appropriate regulation of the KRAS gene, exhibited a Dr. Jekyll and Mr. Hyde duality....

2010-10-27 02:21:47

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA. "Recent retrospective correlative analyses of...

2010-10-26 11:13:45

(Ivanhoe Newswire) -- Taking back the years the fears and anxieties of having cancer may have brought are possible. Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Systemic chemotherapy is treatment with anticancer drugs that travel through the bloodstream, reaching and affecting cells all over the body. While radiation therapy utilizes x-rays at very high doses to...

2010-10-25 23:48:19

Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Now a new study suggests outcomes are also better when radiation therapy is combined with cetuximab, a targeted therapy. The data will be presented at the annual meeting of the American Society for Radiation Oncology, October 31st through November 4th in San Diego. The study, conducted at Georgetown Lombardi...

2010-10-12 18:07:56

New data reported at the 35th ESMO Congress A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have...

2010-10-12 16:42:21

Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Professor Kjell Magne Tveit from Oslo University Hospital, Norway, reported the unexpected results from the NORDIC VII study, which included 566 patients from Sweden, Denmark,...

2010-10-04 16:05:00

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology. "Both studies demonstrated that Vectibix administered with chemotherapy...

2010-09-22 11:31:00

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from...

2010-09-08 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the...